Copyright Reports & Markets. All rights reserved.

Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 PCR
    • 1.2.3 In-situ Hybridization
    • 1.2.4 Immunohistochemistry
    • 1.2.5 Sequencing
    • 1.2.6 Others
  • 1.3 Market by Application
    • 1.3.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Oncology
    • 1.3.3 Neurological Disorders
    • 1.3.4 Cardiovascular Disease
    • 1.3.5 Immunological Disorders
    • 1.3.6 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Perspective (2016-2027)
  • 2.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Growth Trends by Regions
    • 2.2.1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Historic Market Share by Regions (2016-2021)
    • 2.2.3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Regions (2022-2027)
  • 2.3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Industry Dynamic
    • 2.3.1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Trends
    • 2.3.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Drivers
    • 2.3.3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Challenges
    • 2.3.4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players by Revenue
    • 3.1.1 Global Top Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players by Revenue (2016-2021)
    • 3.1.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Players (2016-2021)
  • 3.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue
  • 3.4 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Concentration Ratio
    • 3.4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue in 2020
  • 3.5 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Key Players Head office and Area Served
  • 3.6 Key Players Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Solution and Service
  • 3.7 Date of Enter into Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Breakdown Data by Type

  • 4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Historic Market Size by Type (2016-2021)
  • 4.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Type (2022-2027)

5 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Breakdown Data by Application

  • 5.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Historic Market Size by Application (2016-2021)
  • 5.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2016-2027)
  • 6.2 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
    • 6.2.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2021)
    • 6.2.2 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2022-2027)
    • 6.2.3 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2027)
  • 6.3 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
    • 6.3.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2021)
    • 6.3.2 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2022-2027)
    • 6.3.3 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2027)
  • 6.4 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country
    • 6.4.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2016-2021)
    • 6.4.2 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.3 Canada

7 Europe

  • 7.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2016-2027)
  • 7.2 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
    • 7.2.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2021)
    • 7.2.2 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2022-2027)
    • 7.2.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2027)
  • 7.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
    • 7.3.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2021)
    • 7.3.2 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2022-2027)
    • 7.3.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2027)
  • 7.4 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country
    • 7.4.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2016-2021)
    • 7.4.2 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2016-2027)
  • 8.2 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
    • 8.2.1 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
    • 8.3.1 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Region
    • 8.4.1 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2016-2027)
  • 9.2 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
    • 9.2.1 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2021)
    • 9.2.2 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2022-2027)
    • 9.2.3 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2027)
  • 9.3 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
    • 9.3.1 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2021)
    • 9.3.2 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2022-2027)
    • 9.3.3 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2027)
  • 9.4 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country
    • 9.4.1 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2016-2021)
    • 9.4.2 Latin America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2016-2027)
  • 10.2 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type
    • 10.2.1 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application
    • 10.3.1 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country
    • 10.4.1 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Qiagen NV
    • 11.1.1 Qiagen NV Company Details
    • 11.1.2 Qiagen NV Business Overview
    • 11.1.3 Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 11.1.4 Qiagen NV Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
    • 11.1.5 Qiagen NV Recent Development
  • 11.2 GE Healthcare
    • 11.2.1 GE Healthcare Company Details
    • 11.2.2 GE Healthcare Business Overview
    • 11.2.3 GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 11.2.4 GE Healthcare Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
    • 11.2.5 GE Healthcare Recent Development
  • 11.3 Agilent Technologies
    • 11.3.1 Agilent Technologies Company Details
    • 11.3.2 Agilent Technologies Business Overview
    • 11.3.3 Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 11.3.4 Agilent Technologies Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
    • 11.3.5 Agilent Technologies Recent Development
  • 11.4 F Hoffman La Roche
    • 11.4.1 F Hoffman La Roche Company Details
    • 11.4.2 F Hoffman La Roche Business Overview
    • 11.4.3 F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 11.4.4 F Hoffman La Roche Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
    • 11.4.5 F Hoffman La Roche Recent Development
  • 11.5 Foundation Medicine
    • 11.5.1 Foundation Medicine Company Details
    • 11.5.2 Foundation Medicine Business Overview
    • 11.5.3 Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 11.5.4 Foundation Medicine Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
    • 11.5.5 Foundation Medicine Recent Development
  • 11.6 Thermo Fisher Scientific Inc.
    • 11.6.1 Thermo Fisher Scientific Inc. Company Details
    • 11.6.2 Thermo Fisher Scientific Inc. Business Overview
    • 11.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 11.6.4 Thermo Fisher Scientific Inc. Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
    • 11.6.5 Thermo Fisher Scientific Inc. Recent Development
  • 11.7 Leica Biosystems Nussloch GmBH
    • 11.7.1 Leica Biosystems Nussloch GmBH Company Details
    • 11.7.2 Leica Biosystems Nussloch GmBH Business Overview
    • 11.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 11.7.4 Leica Biosystems Nussloch GmBH Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
    • 11.7.5 Leica Biosystems Nussloch GmBH Recent Development
  • 11.8 Pfizer
    • 11.8.1 Pfizer Company Details
    • 11.8.2 Pfizer Business Overview
    • 11.8.3 Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 11.8.4 Pfizer Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2016-2021)
    • 11.8.5 Pfizer Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

    Segment by Type
    PCR
    In-situ Hybridization
    Immunohistochemistry
    Sequencing
    Others

    Segment by Application
    Oncology
    Neurological Disorders
    Cardiovascular Disease
    Immunological Disorders
    Others

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia
    Latin America
    Mexico
    Brazil
    Rest of Latin America
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of MEA

    By Company
    Qiagen NV
    GE Healthcare
    Agilent Technologies
    F Hoffman La Roche
    Foundation Medicine
    Thermo Fisher Scientific Inc.
    Leica Biosystems Nussloch GmBH
    Pfizer
    F Hoffman La Roche

    Buy now